designed to intensify or boost specific immune responses to modify or control these presently incurable diseases. We believe that our products will allow people to live a better, healthier and longer life.

Our proprietary Immunetherapy Platform Technology includes a plasmid DNA-based antigen, a nanomedicine formulation and a topical administration device that targets antigens to dendritic cells. Our technologies support the rapid and cost-effective development of original biologic products for several indications and provides tools for the selection of an optimal treatment regime for patients, based on his or her disease and genetic background.

Our Lead Product Candidate for the treatment of HIV/AIDS, called "DermaVir", is a therapeutic HIV vaccine effective in boosting immune responses that kill HIV-infected cells. Our preclinical, Phase I, Phase I/II and Phase II clinical trials have demonstrated boosting of HIV-specific T cells and specific killing of HIV-infected cells that are not eliminated by current antiretroviral drugs. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. The goal of DermaVir immune intensification is to modify HIV disease, decrease antiretroviral drug exposure while maintaining undetectable HIV-RNA levels, thereby achieving a remission (functional cure) in HIV-infected patients.

We also have an extensive pipeline of product candidates, a number of which have animal proof of concept, for example, for the treatment of Chlamydia, called "ChlamyDerm" and our allergen-specific immunotherapy, called "DermAll". ChlamyDerm has successfully decreased the amount of infected cells together with infection-associated inflammation in mice experiments. DermAll decreased the allergic symptoms by balancing allergen-specific immune responses in mice experiments.

Our other pipeline candidates for virus-associated cancers and warts are in discovery phase.

Genetic Immunity is a wholly owned subsidiary of Power of the Dream ventures, Inc.